Newmarket

IgniteData

The future of healthcare and life sciences research

The importance of improving the UK's data infrastructure

EVENT BROCHURE

Supported by

ZS

VULCAN HL7 FHIR

Table of Contents

Overview

The UK's national healthcare system collects data about its entire population from cradle to grave, creating a unique data asset that can be used to deliver improvements in the way services are delivered as well as research.

However, interoperability has been one of the key barrier to the effective use of NHS data for over a decade, with reports like the Wachter Review highlighting its critical role in unlocking the potential of healthcare data.

The recent Sudlow Review provides an exciting opportunity to take action, proposing that interoperability could be improved through the application of information standards to IT suppliers within the health and social care system, as part of the forthcoming Digital Information and Smart Data Bill.

The Bill introduces a legal mechanism that could make interoperability mandatory. Under these provisions, the Secretary of State could issue a written notice to any IT provider suspected of non-compliance, requiring them to meet the standard within a set timeframe or provide evidence of compliance.

This approach marks a step in the right direction by potentially allowing the NHS to mandate and actually enforce interoperability requirements more effectively, paving the way for improved data sharing and better support for research and innovation.

This invitation-only conference will bring together senior NHS leaders, civil servants, and key stakeholders from across the healthcare and life sciences sectors to explore how the UK can move from rhetoric to meaningful action in addressing these long-standing challenges.

By examining both UK and international approaches–such as the US's adoption of FHIR standards–delegates will gain valuable insights into the strategies needed to overcome interoperability barriers and improve data access for research and clinical trials.

The event will also focus on how the NHS's and the Department of Health and Social Care's national policies can be operationalised to ensure that progress is made, offering a unique opportunity to influence the future of the UK's data infrastructure and healthcare research landscape.

Agenda

Thursday 1st May 2025 from 1.45 - 6pm

Arrival at 1.45 pm for a start at 2 pm

2.00-2.45 pm – Lord James O'Shaughnessy in conversation with Prof Cathie Sudlow OBE

The session will explore the findings and recommendations of the Sudlow review in the context of the research and clinical trials landscape in the UK. It will seek to set the scene for the rest of the conference on the importance of improving access to data for research purposes and the barriers academics and industry face, with a focus on interoperability.

Speakers:

- **Lord James O'Shaughnessy**, Senior Partner, Newmarket Strategy
- **Professor Cathie Sudlow**, OBE, author of the Independent Review into the UK health data landscape

2.45-3.30pm – Panel session 1: Overcoming data access challenges: Lessons from abroad

This panel will explore how other countries have tackled data access in healthcare, offering valuable lessons for the UK.

Focusing on global best practices, panellists will highlight key examples, including the US, where the adoption of standards like FHIR (Fast Healthcare Interoperability Resources) has been mandated by law. Panellists will discuss how such standards have been implemented, the impact they've had on accessing healthcare data, and the lessons learned from these international experiences.

Speakers:

- **Amy Cramer**, Clinical Innovation Focus Area Lead, Johnson & Johnson
- **Rachel Enright**, Executive Director, Late Development Oncology Clinical Operations, AstraZeneca
- **Angela, Fritsche,** M.P.A, Administrator and Instructor of Health Care Administration, Mayo Clinic Comprehensive Cancer Center
- **Joe Lengfellner**, Senior Director, Clinical Research Informatics & Technology, Memorial Sloan Kettering Cancer Center
- **Michel Rider**, Global Head of Digital R&D, Sanofi
- **Dr Mats Sundgren**, Senior Industry Scientific Director, i~HD (European Institute for Innovation through Health Data) - Chair

BREAK

Agenda

3.45-4.30 pm – Panel session 2: Improving the ability to access and use data: the role of interoperability.

This panel will explore the role interoperability plays in improving access to and use of healthcare data for patient benefit, operational improvements, dealing with pressing challenges such as the NHS's waitlist as well as research.

The Department of Health and Social Care and the NHS's national policy on interoperability is key to the better use of data in the NHS and its transformation, but what does it mean to operationalise these policies in practice?

Panellists will discuss strategies to promote data interoperability across the healthcare system. They will share real-world experiences of the challenges faced when integrating disparate data systems and how these barriers are being overcome. The discussion will also focus on the support needed from NHS England to accelerate progress.

Speakers:

- **Dr Sarah Burge,** Director of Clinical Integration, Cambridge University Foundation Trust
- **James McDermott,** Head of Vulcan, HL7
- **Dr Janet Valentine**, Executive Director Innovation and Research Policy, The Association of the British Pharmaceutical Industry
- **Dr Joe Zhang**, Head of Data Science (London SDE), Artificial Intelligence Centre for Value Based Healthcare
- **Steve Tolle**, Chief Product and Technology Officer, IgniteData – Chair

4.30-4.45 pm – Closing speech

- **Lord Ara Darzi**, Co-Director of the Institute of Global Health Innovation and Professor of Surgery, Department of Surgery & Cancer - Faculty of Medicine, Imperial College London

4.45-6.00 pm – Networking and drinks

Highlight on speakers

Professor the Lord Darzi of Denham OM KBE PC FRS, Paul Hamlyn Chair of Surgery and Co-Director, Institute of Global Health Innovation, Imperial College London

Professor Darzi is the Paul Hamlyn Chair of Surgery and Co-Director of the Institute of Global Health Innovation at Imperial College London. He is a Consultant Surgeon at the Imperial College Hospital NHS Trust and Royal Marsden NHS Foundation Trust. Professor Darzi is Chair of the NHS Accelerated Access Collaborative and Chair for the Pre-emptive Health & Medicine Initiative at Flagship Pioneering, United Kingdom. In 2024, at the request of the Secretary of State, he completed an Independent investigation of the NHS in England.

Professor Darzi is also the Executive Chair of the Fleming Initiative, an innovative programme under the patronage His Royal Highness the Prince of Wales, to address the rising burden of antimicrobial resistance worldwide through an inter-disciplinary approach.
He is a Fellow of the Academy of Medical Sciences and the Royal Society, Honorary Fellow of the Royal Academy of Engineering and Past President of the British Science Association.

In 2002, Professor Darzi was knighted for his services to medicine and surgery, and in 2007 was introduced as Lord Darzi of Denham to the United Kingdom's House of Lords as the Parliamentary Under-Secretary of State for Health. He has been a member of His Majesty's Most Honourable Privy Council since 2009 and was awarded the Order of Merit in 2016

Professor Cathie Sudlow, OBE, author of an independent review of the UK-wide health data landscape, Strategic Adviser to Health Data Research UK (HDR UK), Director of the Usher Institute at the University of Edinburgh and Director of the Adolescent Health Study

Until 2024, Professor Sudlow was Chief Scientist and Deputy Director of HDR UK, and Director of the British Heart Foundation Data Science Centre. She was also the first Research Director for HDR UK in Scotland.

In 2023, Prof Sudlow was commissioned by the Chief Medical Officer for England, the UK National Statistician and NHS England to undertake an independent review of the UK-wide health data landscape. "Uniting the UK's Health Data: A Huge Opportunity for Society" was published in November 2024, it sets out a bold vision for how the barriers and inefficiencies that currently delay the safe and secure use of health data to improve lives can be overcome, with key recommendations to transform the health data ecosystem.

Over the last 15 years, her focus has been on leading large-scale, collaborative, open-science initiatives that enable a better understanding of the causes and consequences of health and disease across the life course, leading to new and improved approaches to prevention, diagnosis and treatment. From 2020, Cathie worked with NHS Digital (and then NHS England) to develop NHS England's first secure data environment to hold and enable access for research to linked health data from multiple sources for the whole population of England.
From 2011 to 2019, as Chief Scientist for UK Biobank, she led efforts to follow the health of UK Biobank participants through linkage to national health datasets.

As a neurology specialist doctor with over 30 years working in the NHS, Prof Sudlow's clinical work has focused mainly on the assessment and treatment of patients with suspected stroke. Cathie is a Fellow of the Academy of Medical Sciences and of the Royal Society of Edinburgh. She was awarded an OBE for services to medical research in 2020.

Highlight on speakers

Lord James O'Shaughnessy, Senior Partner, Newmarket Strategy

James has operated at the highest levels of government, including as a Minister at the Department for Health & Social Care, as Director of the No.10 Policy Unit, and as an advisor to DHSC Ministers during the COVID-19 crisis. As Minister his responsibilities included implementing the Life Science Industrial Strategy, delivering a new pricing scheme with the pharmaceutical industry, chairing the National Genomics Board, and driving the digital transformation of the NHS. He was also responsible for preparing the health and social care sectors for Brexit and helping to design the post-Brexit regulatory regime. In early 2023 James was commissioned by the Government to carry out an independent review of commercial clinical trials in the UK, which was published in May of that year.

James is co-founder and Senior Partner of Newmarket Strategy, a consultancy dedicated to improving access to health innovation by providing strategic advice and technical support to the healthcare, life sciences and health tech sectors. At Newmarket, James provides senior counsel to multinationals, SMEs, investors, universities and charities across health and life sciences, with a particular focus on technology, digital and data.

James is a Life Peer in the House of Lords, Chair of Cambridge University Health Partners (CUHP), a Visiting Professor at the Institute of Global Health Innovation at Imperial College, a Trustee of HDR-UK, a non-executive director of Albion Development VCT plc, and Patron and Strategic Adviser to the Tessa Jowell Brain Cancer Mission. In 2023 James led and published an independent review of commercial clinical trials in the UK for HM Government.

Dr Sarah Burge, Director of Clinical Integration, Cambridge University Foundation Trust

Dr. Sarah Burge is a senior leader in translational oncology and data-driven healthcare innovation. As Director of Clinical Integration at the University of Cambridge and Development Lead for the Integrated Cancer Medicine (ICM) Programme, she is at the forefront of a radical transformation in cancer care–where research and clinical delivery are seamlessly aligned.he plays a central role in the development of the Cambridge Cancer Research Hospital, helping to shape a new model of care where research and clinical practice are tightly interwoven.

Dr. Burge brings over 15 years of experience working at the intersection of biomedical science, data integration, and healthcare delivery. Her work focuses on building systems and teams that can take innovations–particularly those in AI and data science–through to real-world clinical use.
At Cambridge, she has led projects ranging from the delivery of major COVID-19 research trials to the development of new data platforms for cancer diagnosis and prognosis. She is responsible for ensuring that scientific advances in integrated cancer medicine are supported by the necessary infrastructure, governance, and clinical engagement to reach patients effectively.

Before joining the University of Cambridge, Dr. Burge worked at the Wellcome Trust Genome Campus, where she led bioinformatics initiatives at both the Sanger Institute and EMBL-EBI, with a focus on RNA biology. She continues to collaborate with a wide range of academic, clinical, and industry partners–including GE Healthcare–to deliver translational impact.

Highlight on speakers

Amy Cramer MMCi, BSN, Clinical Innovation Focus Area Lead, Johnson & Johnson and Founder and Chairman of the Board, Vulcan FHIR Accelerator

Amy Cramer is the founder and Chairman of the Board for Vulcan, an international organization made up of multiple research community members representing perspectives such as government agencies, technology vendors, patients, sponsors and sites across the globe. Vulcan is dedicated to positively disrupting the research community through the advancement of electronic exchange of data based on standards. She works for Johnson and Johnson Innovative Medicine focused on Health Innovation and Data Acquisition. With a background as a cardiac critical care nurse, clinical research coordinator, certified healthcare quality professional, and clinical research informaticist, she brings a wealth of experience to her current role. Throughout her career, Ms Cramer has worked in various healthcare settings, including community hospitals, independent academic medical centers, world-class academic centers and pharmaceutical corporations.

In addition to her responsibilities at JJIM, Ms Cramer is actively involved in several industry organizations; iHD eSource Task Force, formerly held roles as Vice Co-Chair for the Society for Clinical Data Management eSource Consortium, Health Level Seven Co-Chair Clinical Interoperability Council and Co-Lead for Gravitate's Work Package 5.Ms Cramer holds a Masters in Management of Clinical Informatics (MMCi) from Duke University School of Medicine and actively participates on the Board of Alumni for the Duke University School of Medicine MMCi program.

Rachel Enright, , RN, CCPE, Executive Director, Late Development Oncology Clinical Operations, AstraZeneca

Rachel Enright is an accomplished leader in the field of clinical operations, with over two decades of experience in oncology drug development. Starting her career in Mississauga, Canada, she relocated to Cambridge, UK, over 7 years ago. Rachel has worked at AstraZeneca for over 28 years and currently serves as the Executive Director of Clinical Operations, where she oversees the operational execution of various cancer portfolios within Late Development Oncology. Her expertise spans all phases of clinical development, particularly in small molecule and immuno-oncology compounds, with a focus on GU, head & neck, and paediatric cancers

Throughout her career, Rachel has demonstrated a strong commitment to mentoring and developing high-performing teams, earning numerous accolades including the AstraZeneca CEO award and Canadian Presidential awards for excellence. Rachel's leadership style is characterized by her strategic thinking, innovative approach, and ability to deliver complex global trials on aggressive timelines and budgets. Rachel is a Registered Nurse and has continually updated her skills through various courses in pharmaceuticals, oncology, and project management. Her contributions to the field extend beyond her executive responsibilities, as she is deeply involved in initiatives aiming to improve clinical trial frameworks and operational efficiencies at AstraZeneca.

Rachel is a Registered Nurse and has continually updated her skills through various courses in pharmaceuticals, oncology, and project management. Her contributions to the field extend beyond her executive responsibilities, as she is deeply involved in initiatives aiming to improve clinical trial frameworks and operational efficiencies at AstraZeneca.

Highlight on speakers

Angela, Fritsche, M.P.A, Administrator and Instructor of Health Care Administration, Mayo Clinic Comprehensive Cancer Center

Angela Fritsche is the Enterprise Administrator for Clinical Research at the Mayo Clinic Comprehensive Cancer Center (MCCCC) and has over 20 years of experience in academic medical centers and higher education research institutions.

She joined the MCCCC 6 years ago to manage protocol development, study conduct and navigated clinical trials through the onset of the COVID-19 pandemic and great resignation.

During her tenure, MCCCC clinical research has successfully transformed operations including decreasing National Cancer Institute activation timelines and increasing accruals. Ms. Fritsche has a passion for bringing technology and innovation to clinical trials to help accelerate bringing hope to patients across the globe. This includes leveraging EHR to EDC which decreases clinical trial costs, improves first time data quality, and provides data faster to assure patient safety oversight and, hopefully, accelerating approval of clinical trials that show improved patient outcomes compared to standard of care.

Ms. Fritsche received a Bachelor of Science in Business Administration – Human Resources Management and a Master of Public Administration with a specialization in Healthcare Administration from West Virginia University, Morgantown, WV. In 2024, she completed a Graduate Certificate in Equity, Diversity, Inclusion and Belonging Leadership at Harvard University, Cambridge, MA.

Joe Lengfellner, Senior Director of Clinical Research Informatics & Technology at Memorial Sloan Kettering Cancer Center, USA

Joe Lengfellner brings over 20 years of experience in healthcare IT and clinical research, with a career focused on driving innovation at the intersection of technology and clinical trial operations. A recognized pioneer in EHR-to-EDC integration, Joe has authored multiple publications and case studies highlighting real-world implementations that improve data quality, streamline workflows, and reduce site burden.

As the leader of a 50-person clinical research technology team at Memorial Sloan Kettering Cancer Center in New York City, Joe has advocated for forward-thinking strategies such as decentralized clinical trials, FHIR-based interoperability, and eSource adoption, initiatives that have significantly improved the experience for patients, clinicians, and research staff alike.

Joe also co-founded and leads the Clinical Research Innovation Consortium (CRIC), a collaborative network of leading academic research sites, sponsors, and technology partners focused on accelerating the evaluation, validation, and scaling of digital solutions in clinical trials. Under his leadership, CRIC has become a trusted model for de-risking emerging technologies and aligning the ecosystem around standards and outcomes-focused innovation.

His expertise spans digitized trial design, clinical operations, advanced analytics, and the deployment of eClinical tools that support more efficient and higher quality clinical trials.

Highlight on speakers

James McDermott, Head of Vulcan, HL7

With over 30 years of experience in medical statistics, clinical research, and healthcare data sciences, he has established himself as a pioneering leader and innovator. Currently serving Head of Vulcan where his role focuses on advancing the growth and development of the HL7 Vulcan accelerator initiative. He is also Executive Chairman & CEO at Achieve Intelligence, he specialises in leveraging advanced data analytics and AI to deliver tailored business intelligence solutions, particularly in the healthcare sector. He has founded and lead multiple successful organisations, where he has driven strategic initiatives and transformative projects.

His expertise encompasses leadership and strategic planning, development of innovative business and statistical strategies, and extensive participation in industry conferences. He has a proven track record of empowering SMEs through strategic investment and advisory services, ensuring robust, ethical business foundations.

In addition to his professional roles, he is an active contributor to the academic and professional community, regularly presenting at conferences such as Phuse Connect and Domino Rev4 on topics ranging from design thinking in leadership to advancements in biopharma data standardisation.

Michel Rider, Global Head of Digital R&D, Sanofi

Michel is Sanofi's Global Head of Digital R&D and is accountable for all applications, data, and AI/ML assets applied to discovery, development, and market support of medicines and vaccines. Prior to this she held leadership roles at GSK and Merck in both business and digital/IT, was management consultant with Accenture, and led a commercial software company focused on digitalizing clinical patient dataflow. She holds a BS in Microbiology and an MS in Management of Information Systems.

Highlight on speakers

Mats Sundgren, PhD, Sr. Industry Science Director, i-HD

Mats Sundgren, PhD, MSc, is a distinguished authority in Health Data Strategy, serving both industry and academia. With an impressive career spanning over 37 years in the pharmaceutical industry, Mats has made significant contributions across various domains, including Discovery, Development, Manufacturing, IT R&D, Patents, Clinical Science, and Data Science & AI. His work places him at the forefront of technological innovation in the field. In 2022, following an illustrious 12-year tenure as the global integration lead for Electronic Health Records (EHR) services at AstraZeneca, Mats expanded his professional endeavors.

He now holds several key roles: Sr. Industry Scientific Director and co-founder of the i-HD (European Institute for Innovation through Health Data), Executive Strategic Advisor for IgniteData, which develops a system-agnostic EHR-to-EDC solution for clinical trials, and Chairman of the Board of the Research Foundation IMIT (Institute of Managing Innovation and Technology). IMIT includes prominent institutions such as Chalmers University of Technology, Royal Institute of Technology, Lund University of Technology, and Stockholm School of Business. Additionally, he serves as a Board Member of the Center for Health Governance at Gothenburg University. In July 2024, Mats assumed the role of Scientific Adviser for IOMED, a company specializing in AI-powered technology for healthcare data activation. In March 2025, assumed the role of R&D Strategy Advisor for ZS Associates.

Mats has an extensive portfolio of work, including over 80 publications, books, and patents in Life Science, Economics, and Social Science. His areas of expertise encompass Health Data Science & AI, Clinical Science, Clinical Trials Management, Business Modelling, Innovation & Creativity Management, and Device Development.

Steven Tolle, Chief Product & Technology Officer, IgniteData

Steven Tolle is Chief Product & Technology Officer at IgniteData where he oversees product strategy, development and marketing. He also serves on the advisory board for HLM Investment Partners. He has over 30 years of commercial health care technology expertise in the areas of product management, strategy and business development. Steve has spent his career helping to develop and manage some of the most important themes in health care innovation today, including artificial intelligence, diagnostic imaging/medical devices, electronic health records, population health, managed care and value-based pharmaceutical pricing.

Prior to joining IgniteData, Steve was a General Partner at HLM Investment Partners. Previously, he was Global Vice President for Strategy at IBM Watson Health, where he led strategy and corporate development for the Merge Healthcare medical imaging business unit (acquired by IBM for $1B in 2015). Steve led the effort to move Merge Healthcare into the AI space and played a key role in the successful sale to IBM.

Other notable previous roles include Senior Vice President/General Manager at Optum, Vice President of Product Management at Allscripts, and Director of Business Development & Product Management at Pfizer

Highlight on speakers

Janet Valentine PhD, Executive Director Innovation and Research Policy, The Association of the British Pharmaceutical Industry

Janet has extensive experience in strategic leadership positions in the UK health research and health data research environment. As Executive Director of Innovation and Research Policy at the Association of the British Pharmaceutical Industry (ABPI), Janet is responsible for influencing Government policy to make the UK a globally attractive destination to discover and develop new medicines and vaccines.

Prior to joining the ABPI, Janet was the Industrial Strategy Challenge Fund Director for Data to Early Diagnosis and Precision Medicine at Innovate UK, where she oversaw a broad portfolio of investments in genomics, health data, AI, medical imaging and digital pathology. In her previous role as an Executive Director at the Medicines and Healthcare Products Regulatory Agency (MHRA), Janet led the Clinical Practice Research Datalink (CPRD). CPRD is the UK's largest dedicated health data research service, providing research data services to industry, academia and regulators worldwide. Janet's previous roles include Head of Population Health and Health Informatics at the Medical Research Council and Deputy Chief Executive of the UK Clinical Research Collaboration.



Dr. Joe Zhang, Head of Data Science at the Artificial Intelligence Centre for Value-Based Healthcare and London Secure Data Environment

Joe is a specialist doctor and a data engineer/scientist, with more than a decade's experience working in technical programmes across the NHS, academia, and in industry. During the COVID-19 pandemic, he worked as a Senior Fellow in ECMO at Guy's and St. Thomas' Hospital, whilst leading development of national data infrastructure and machine learning tools to support COVID-19 referral pathways.Joe was previously a Wellcome Fellow at the Institute of Global Health Innovation undertaking a PhD in data-centric artificial intelligence, before working at Arcturis Data, building Real-World Data capabilities for supporting external control arm studies.

At the AI Centre and the London SDE, Joe is responsible for the development of multi-modal data lakes across London NHS Trusts, and the application of data science and predictive analytics across a London-wide data ecosystem. His team is pioneering the use of Large Language Models for deep phenotyping of unstructured patient records, opening new doors to precision medicine, medical foundation models, and capabilities for live clinical trial recruitment.

Venue

The Royal Society of Medicine (RSM) stands in the heart of London, carrying a long tradition of sharing and advancing medical knowledge. Founded in 1805 as the Medical and Chirurgical Society, it has evolved into a respected institution focused on improving healthcare for better lives.

Home to over 20,000 members across 50 specialist areas, the RSM houses one of the world's most comprehensive medical libraries. With its convenient central London location and a legacy of fostering multidisciplinary collaboration, the RSM provides a unique and inspiring setting for our conference. Attendees will experience the Society's rich heritage, gain insights from experts, and join a global network dedicated to advancing healthcare

About Newmarket

Newmarket Strategy is a dedicated healthcare strategy and market access consultancy, bringing a range of technical knowledge and policy insight to complex challenges across healthcare and life sciences.

Our team of experts includes a former Minister, the longest serving Adviser to a UK Health Secretary, the UK's leading expert in navigating HTA processes, NHS England's former Commercial Medicines Director, national NHS leaders of independent sector commissioning and elective care recovery, an expert in the field of digital health and software as medical device, as well as experienced analysts and consultants.

We work with several major provider organisations including major NHS trusts, major pharmaceutical companies, the UK's largest primary care operator and world-class research institutions. We also work with an array of digital health providers – covering products, services, and digital therapeutics – bringing innovative solutions to the health and life science sectors.

About

IgniteData

IgniteData is a leading innovator in clinical research technology, transforming how hospitals and research sites transfer patient data for clinical trials. Our cutting-edge Archer technology streamlines data connectivity, reducing inefficiencies and accelerating the delivery of life-changing treatments to patients.

Our team brings together experts in clinical research, data security, and healthcare technology, working alongside global pharmaceutical leaders and top-tier research institutions.

We partner with 75% of the top comprehensive cancer centers, operate across four continents, and maintain 99.999% data accuracy–ensuring research teams can focus on discovery rather than data management.

We collaborate with research organizations, hospitals, and industry leaders to modernize clinical trials, upholding the highest standards of trust, security, and efficiency. Through our commitment to innovation and operational excellence, we are redefining study data interconnectivity and shaping the future of clinical research.

Learn more at www.ignitedata.com.



Contact Us

Address

The Smiths Building
179 Great Portland Street
London W1W 5PL
United Kingdom

Phone Number

+44 (0) 207 368 1611

Email Adress

www.newmarket-strategy.com